Page 153 - Read Online

Page 14 of 17 Li et al. J Cancer Metastasis Treat 2020;6:14 I http://dx.doi.org/10.20517/2394-4722.2020.27

5. Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet
2018;50:645-51.
6. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature
2008;455:1069-75.
7. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al. The mutational landscape of head and neck squamous cell carcinoma.
Science 2011;333:1157-60.
8. Santarpia L, Bottai G, Kelly CM, Gyorffy B, Szekely B, et al. Deciphering and targeting oncogenic mutations and pathways in breast
cancer. Oncologist 2016;21:1063-78.
9. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, et al. Multiplatform analysis of 12 cancer types reveals molecular
classification within and across tissues of origin. Cell 2014;158:929-44.
10. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, et al. Comprehensive characterization of cancer driver genes and
mutations. Cell 2018;174:1034-5.
11. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, et al. Approval summary for imatinib mesylate capsules in the treatment of
chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-42.
12. Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, et al. FDA approval summary: crizotinib for the treatment of metastatic non-
small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 2014;19:e5-11.
13. Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and molecular classification of lung cancer. Cancer Treat Res 2016;170:25-
46.
14. Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch 2014;465:1-14.
15. Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget 2015;6:4553-61.
16. Offin M, Liu D, Drilon A. Tumor-agnostic drug development. Am Soc Clin Oncol Educ Book 2018;38:184-7.
17. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high
solid tumors. Clin Cancer Res 2019;25:3753-8.
18. Kummar S, Lassen UN. TRK Inhibition: a new tumor-agnostic treatment strategy. Target Oncol 2018;13:545-56.
19. Scott LJ. Larotrectinib: first global approval. Drugs 2019;79:201-6.
20. Al-Salama ZT, Keam SJ. Entrectinib: first global approval. Drugs 2019;79:1477-83.
21. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive
solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-82.
22. Schram AM, Chang MT, Jonsson P, Drilon A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Nat Rev Clin Oncol 2017;14:735-48.
23. Tuna M, Amos CI, Mills GB. Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors. Oncotarget
2019;10:2095-111.
24. Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Satoh Y, et al. Mechanism of oncogenic signal activation by the novel fusion kinase
FGFR3-BAIAP2L1. Mol Cancer Ther 2015;14:704-12.
25. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
26. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-
nodal metastases. Nature 1987;328:170-2.
27. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, et al. Driver fusions and their implications in the development and treatment
of human cancers. Cell Rep 2018;23:227-38.e3.
28. Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res 2012;18:930-7.
29. Davare MA, Tognon CE. Detecting and targetting oncogenic fusion proteins in the genomic era. Biol Cell 2015;107:111-29.
30. Farago AF, Azzoli CG. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.
Transl Lung Cancer Res 2017;6:550-9.
31. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N
Engl J Med 2010;363:1693-703.
32. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced
non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013;14:590-8.
33. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med
2014;370:1189-97.
34. Ou SH, Weitz M, Jalas JR, Kelly DF, Wong V, et al. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7
years) history of brain radiation. Lung Cancer 2016;96:15-8.
35. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
36. Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol
2020; doi: 10.1016/j.jhep.2020.03.007.
37. Yu YP, Liu P, Nelson J, Hamilton RL, Bhargava R, et al. Identification of recurrent fusion genes across multiple cancer types. Sci Rep
2019;9:1074.
38. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, et al. Development and validation of a clinical cancer genomic profiling
test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-31.
39. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM,
in non-Hodgkin’s lymphoma. Science 1995;267:316-7.